Esperion Therapeutics

ESPR60

Penny Stock

$1.68arrow_drop_down4.00%-$0.07

Penny Stock

ESPR60

$1.68

arrow_drop_down4.00%-$0.07

Penny Stock

Performance History

Key Stats
Open	$1.73
Prev. Close	$1.75
EPS	-0.85
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$329.65M
PE Ratio	-

	LOW	HIGH
Day Range	1.68	1.74
52 Week Range	0.70	3.40

Ratios







EPS	-0.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc (ESPR) is a biopharmaceutical company that focuses on the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is bempedoic acid, also known as ETC-1002, which is being developed as an adjunct to diet and maximally tolerated statin therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease (ASCVD). Bempedoic acid is designed to lower LDL-C levels, thus reducing the risk of cardiovascular events.

The history of Esperion Therapeutics Inc can be traced back to 1998 when the company was founded. Over the years, the company has focused on the development of innovative therapies for the treatment of high cholesterol. In 2015, Esperion Therapeutics went public and its stock has been traded on the NASDAQ under the ticker symbol "ESPR". Since then, the company has made significant progress in its research and development efforts, and its stock price has experienced both highs and lows.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Sheldon L. Koenig
Headquarters: Ann Arbor
Employees: 199
Exchange: NASDAQ

Keep an eye on Esperion Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Esperion Therapeutics 's (ESPR) price per share?

The current price per share for Esperion Therapeutics (ESPR) is $1.68. The stock has seen a price change of -$0.07 recently, indicating a -4% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Esperion Therapeutics (ESPR)?

For Esperion Therapeutics (ESPR), the 52-week high is $3.4, which is 102.38% from the current price. The 52-week low is $0.7, the current price is 140% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Esperion Therapeutics (ESPR) a growth stock?

Esperion Therapeutics (ESPR) has shown an average price growth of 0.41% over the past three years. It has received a score of 21 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Esperion Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Esperion Therapeutics (ESPR) stock price performance year to date (YTD)?

As of the latest data, Esperion Therapeutics (ESPR) has a year-to-date price change of -42.47%. Over the past month, the stock has experienced a price change of -4.55%. Over the last three months, the change has been -23.98%. Over the past six months, the figure is -20.38%. Looking at a longer horizon, the five-year price change stands at -95.37%.

help

Is Esperion Therapeutics (ESPR) a profitable company?

Esperion Therapeutics (ESPR) has a net income of -$209.25M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 62.67% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 3.49% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $116.33M, with a revenue growth rate of 54.14%, providing insight into the company's sales performance and growth. The gross profit is $72.9M. Operating income is noted at -$155.56M. Furthermore, the EBITDA is $4.99M.

help

What is the market capitalization of Esperion Therapeutics (ESPR)?

Esperion Therapeutics (ESPR) has a market capitalization of $329.66M. The average daily trading volume is 3.04M, indicating the stock's liquidity and investor engagement.